BioLife Solutions, Inc.
BLFSHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframePart of the healthcare sector, BioLife Solutions, Inc. (BLFS) is listed under Medical Instruments & Supplies. The $1.89B market capitalization puts BLFS squarely in small-cap range for its industry. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Market Cap
$1.89B
Beta
1.82
P/E (TTM)
39.00
P/E (Fwd)
117.00
EPS (TTM)
$0.99
EPS (Fwd)
$0.33
ROE
12.8%
ROA
0.3%
Cash
$82.4M
Total Debt
$15.7M
Free CF
$4.7M
52W Change
41.2%
Annual Financials
Cash vs Debt
Where BLFS stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, BLFS finished 40.20% above its 150-day moving average ($27.54) and 45.04% above its 200-day moving average ($26.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLFS overbought or oversold?
At the October 6, 2026 close, BLFS's RSI(14) was 62.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $82.4M in cash comfortably exceeding the $15.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $4.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 12.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $76.2M (2022) to $96.2M (2025), reflecting a 26% increase over the period.
BioLife Solutions, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, BLFS has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioLife Solutions, Inc.'s trajectory.